ENDPOINTS

Callio emerges with $187M and ADCs from a decade-old Singapore biotech

Frazier Life Sciences and a cadre of well-known biotech investors are coming together for a new startup in the antibody-drug conjugates field, an area of cancer treatment R&D that has remained hot. Investors are pumping ...

Mar 3, 2025 - 15:02
 0
Callio emerges with $187M and ADCs from a decade-old Singapore biotech
Frazier Life Sciences and a cadre of well-known biotech investors are coming together for a new startup in the antibody-drug conjugates field, an area of cancer treatment R&D that has remained hot. Investors are pumping ...
Read More

Tags:

Previous Article

Pearl Young, the first woman to work in a technical role at NASA, overcame barri...

Next Article

Anti-CRO Lindus Health Raises $55M in Series B Funding to Transform the Clinical...

Related Posts

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

Novo Nordisk signs $354M partnership with AI-guided bio...

Mar 3, 2025  0

Bourla praises Trump as RFK Jr. preps vaccine review; Will CRISPR matter?; Atomwise hires new CEO; and more

Bourla praises Trump as RFK Jr. preps vaccine review; W...

Feb 22, 2025  0

CHMP recommends Regeneron, Novartis drugs that still await FDA approval

CHMP recommends Regeneron, Novartis drugs that still aw...

Feb 28, 2025  0